Asada, A; Doi, T; Tagami, T; Takeda, A; Satsuki, Y; Kawaguchi, M; Nakamura, A; Sawabe, Y. Cannabimimetic activities of cumyl carboxamide-type synthetic cannabinoids Forensic Toxicol., 1 Jan 2018, 36 (1), 170-177. 585 kB. https://doi.org/10.1007/s11419-017-0374-9 #8 MS,NMR
Mella-Raipán, J; Lagos, C; Recabarren-Gajardo, G; Espinosa-Bustos, C; Romero-Parra, J; Pessoa-Mahana, H; Iturriaga-Vásquez, P; Pessoa-Mahana, C. Design, Synthesis, Binding and Docking-Based 3D-QSAR Studies of 2-Pyridylbenzimidazoles—A New Family of High Affinity CB1 Cannabinoid Ligands Molecules, 4 Apr 2013, 18 (4), 3972-4001. 746 kB. https://doi.org/10.3390/molecules18043972 NMR,IR
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #12
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report) Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #1. CP 55,940
Davidson, C; Opacka-Juffry, J; Arevalo-Martin, A; Garcia-Ovejero, D; Molina-Holgado, E; Molina-Holgado, F. Spicing up pharmacology: A review of synthetic cannabinoids from structure to adverse events In Adv. Pharmacol.; , Elsevier, 1 Jan 2017; pp 135–168. 458 kB. https://doi.org/10.1016/bs.apha.2017.05.001 #CP-55940
EMCDDA. Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2018. 831 kB. #CP-55,490 IR,UV
EMCDDA. Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2018. 736 kB. #CP-55,490 IR,UV
EMCDDA. Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Mar 2017. 765 kB. #CP 55,490 IR,UV
Chicca, A; Schafroth, MA; Reynoso-Moreno, I; Erni, R; Petrucci, V; Carreira, EM; Gertsch, J. Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high Sci. Adv., 1 Oct 2018, 4 (10), eaat2166. 4.7 MB. https://doi.org/10.1126/sciadv.aat2166 #CP55,940 LC,MS,NMR,IR,other
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #5
Banister, SD; Kumar, KK; Kumar, V; Kobilka, BK; Malhotra, SV. Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain Med. Chem. Commun., 22 May 2019, 10 (5), 647–659. 810 kB. https://doi.org/10.1039/C8MD00595H #7
Oyagawa, CRM; de la Harpe, SM; Saroz, Y; Glass, M; Vernall, AJ; Grimsey, NL. Cannabinoid receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines Front. Pharmacol., 20 Nov 2018, 9 (1202). 2.6 MB. https://doi.org/10.3389/fphar.2018.01202 #CP 55,940 LC,MS,NMR
Banister, SD; Arnold, JC; Connor, M; Glass, M; McGregor, IS. Dark classics in chemical neuroscience: Δ9-Tetrahydrocannabinol ACS Chem. Neurosci., 15 May 2019, 10 (5), 2160–2175. 1.8 MB. https://doi.org/10.1021/acschemneuro.8b00651 #10
Patel, M; Manning, JJ; Finlay, DB; Javitch, JA; Banister, SD; Grimsey, NL; Glass, M. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists Biochem. Pharmacol., 1 May 2020, 175 113871. 1.9 MB. https://doi.org/10.1016/j.bcp.2020.113871 #CP55,940
Alam, RM; Keating, JJ. Adding more “spice” to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists Drug Test. Anal., 1 Mar 2020, 12 (3), 297–315. 2.8 MB. https://doi.org/10.1002/dta.2752 #10 Structure 71 has a single bond where a double bond belongs
Al-Zoubi; Morales; Reggio. Structural Insights into CB1 Receptor Biased Signaling Int. J. Mol. Sci., 13 Apr 2019, 20 (8), 1837. 3.4 MB. https://doi.org/10.3390/ijms20081837 #CP55,940
Longworth, M; Reekie, TA; Blakey, K; Boyd, R; Connor, M; Kassiou, M. New-generation azaindole-adamantyl-derived synthetic cannabinoids Forensic Toxicol., 1 Jul 2019, 37 (2), 350–365. 1.3 MB. https://doi.org/10.1007/s11419-019-00466-1 #2 GC,MS,NMR,IR,other
Grafinger, KE; Vandeputte, MM; Cannaert, A; Ametovski, A; Sparkes, E; Cairns, E; Juchli, PO; Haschimi, B; Pulver, B; Banister, SD; Stove, CP; Auwärter, V. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB‐4en‐PICA, MDMB‐4en‐PINACA, ADB‐4en‐PINACA, and MMB‐4CN‐BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays Drug Test. Anal., 21 May 2021, 13 (7), 1412-1429. 4.3 MB. https://doi.org/10.1002/dta.3054 #X
Uchiyama, N; Kikura-Hanajiri, R; Shoda, T; Fukuhara, K; Goda, Y. Isomeric analysis of synthetic cannabinoids detected as designer drugs Yakugaku Zasshi, 1 Jan 2011, 131 (7), 1141–1147. 763 kB. https://doi.org/10.1248/yakushi.131.1141 #(-)-CP 55,940 LC,MS,UV,other
Blaazer, AR; Lange, JHM; van der Neut, MAW; Mulder, A; den Boon, FS; Werkman, TR; Kruse, CG; Wadman, WJ. Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure–activity relationships, physicochemical properties and biological activity Eur. J. Med. Chem., 1 Jan 2011, 46 (10), 5086-5098. 468 kB. https://doi.org/10.1016/j.ejmech.2011.08.021 #3 MS,NMR